Market Watch
Emma Court
Aug. 13, 2018
Other Alzheimer’s strategies may work better or pair together, experts say, but new drugs are neededA closely watched Alzheimer’s study that tested out a major scientific theory of the disease has left some experts questioning the entire approach.
Many drug makers, including Biogen BIIB, -1.12% and Eisai 4523, -1.26% , which were responsible for last month’s trial, designed their approach around a decades-old theory of the degenerative disease.
But there hasn’t been a lot to show for it, including a number of recent high-profile drug failures. And recent results from a phase 2 trial of Biogen and Eisai’s Alzheimer’s drug BAN2401, though ostensibly positive, may not change the larger picture.
More...
https://www.marketwatch.com/story/theres-new-evidence-that-the-dominant-approach-to-alzheimers-may-be-completely-wrong-2018-08-09?mod=newsviewer_click